

# Samantha Solito

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8399198/publications.pdf>

Version: 2024-02-01

20  
papers

2,821  
citations

643344

15  
h-index

993246

17  
g-index

22  
all docs

22  
docs citations

22  
times ranked

5317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human MDSCs derived from the bone marrow maintain their functional ability but have a reduced frequency of induction in the elderly compared to pediatric donors. <i>Immunity and Ageing</i> , 2020, 17, 27.	1.8	8
2	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
3	The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. , 2019, 7, 58.		109
4	Methods to Measure MDSC Immune Suppressive Activity <i>In Vitro</i> and <i>In Vivo</i> . <i>Current Protocols in Immunology</i> , 2019, 124, e61.	3.6	35
5	Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma. <i>Oncolimmunology</i> , 2018, 7, e1440931.	2.1	22
6	Induction of immunosuppressive functions and NF- $\kappa$ B by FLIP in monocytes. <i>Nature Communications</i> , 2018, 9, 5193.	5.8	45
7	In Brief: Myeloid-derived suppressor cells in cancer. <i>Journal of Pathology</i> , 2017, 242, 7-9.	2.1	26
8	Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. <i>Biomaterials</i> , 2016, 96, 47-62.	5.7	118
9	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>Oncolimmunology</i> , 2016, 5, e1249559.	2.1	51
10	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 35-48.	3.3	68
11	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. <i>Oncotarget</i> , 2016, 7, 1168-1184.	0.8	103
12	Complexity and challenges in defining myeloid-derived suppressor cells. , 2015, 88, 77-91.		119
13	Complexity and challenges in defining myeloid-derived suppressor cells. , 2014, , n/a-n/a.		102
14	Myeloid-derived suppressor cell heterogeneity in human cancers. <i>Annals of the New York Academy of Sciences</i> , 2014, 1319, 47-65.	1.8	349
15	Highlights on Molecular Mechanisms of MDSC-Mediated Immune Suppression: Paving the Way for New Working Hypotheses. <i>Immunological Investigations</i> , 2012, 41, 722-737.	1.0	31
16	Antigen specificity of immune suppression by myeloid-derived suppressor cells. <i>Journal of Leukocyte Biology</i> , 2011, 90, 31-36.	1.5	77
17	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. <i>Blood</i> , 2011, 118, 2254-2265.	0.6	328
18	Myeloid cell diversification and complexity: an old concept with new turns in oncology. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 27-43.	2.7	36

#	ARTICLE	IF	CITATIONS
19	Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBP $\beta$ Transcription Factor. <i>Immunity</i> , 2010, 32, 790-802.	6.6	782
20	IL4R $\alpha$ <sup>hi</sup> Myeloid-Derived Suppressor Cell Expansion in Cancer Patients. <i>Journal of Immunology</i> , 2009, 182, 6562-6568.	0.4	287